Opposite changes in dopamine metabolites and met-enkephalin levels in the ventricular CSF of patients subjected to thalamic electrical stimulation

Clinical Neuropharmacology

Volumn 22, Issue 4, 1999, Pages 231-238

  Bourgoin, Sylvie ^a   Rostaing Rigattieri, Sylvie ^b   Nguyen, Jean Paul ^b   Berberich, Eckart ^b   Duvaldestin, Philippe ^b   Fattaccini, Claude Michelle ^a   Hamon, Michel ^a   Cesselin, François ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Dopamine; Met Enkephalin; Multiple sclerosis; Parkinson's disease; Thalamic electrical stimulation; Ventricular CSF

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; BROMOCRIPTINE; DOPAMINE; HOMOVANILLIC ACID; IOPAMIDOL; LEVODOPA; METENKEPHALIN; PIRIBEDIL;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ELECTROSTIMULATION THERAPY; ESSENTIAL TREMOR; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROTRANSMISSION; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; THALAMUS;

ADULT; AGED; DOPAMINE; ELECTRIC STIMULATION THERAPY; ENKEPHALIN, METHIONINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PARKINSON DISEASE; SEROTONIN; THALAMIC NUCLEI;

EID: 0033455505     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-81.
2. Benabid AL, Pollak P, Gervason C, et al. Long-term suppression of tremor by stimulation of the ventral intermediate thalamic nucleus. Lancet 1991;337:403-6.
3. Limousin P, Pollak P, Benazzouz A, et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-5.
4. Mazars C. Intermittent stimulation of nucleus ventralis posteromedialis for intractable pain. Surg Neurol 1975;4:93-5.
5. Siegfried J. Long-term results of electrical stimulation in the treatment of pain by mean of implanted electrodes (epidural spinal cord and deep brain stimulation). In: Rizzi R, Visentin M, eds. Pain Therapy. Amsterdam: Elsevier; 1983:463-75.
6. Chase TN. Neurochemical alterations in Parkinson's disease. In: Wood JH, ed. Neurobiology of cerebrospinal fluid. New York: Plenum; 1980:207-18.
7. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders 2 - Neurology 7. London: Butterworths; 1987:166-230.
8. Angulo JA, Davis LG, Burkhart BA, Christoph GR. Reduction of striatal dopaminergic neurotransmission elevates striatal proenkephalin mRNA. Eur J Pharmacol 1986;130:341-3.
9. Le Moine C, Normand E, Guitteny AF, Fouque B, Teoule R, Bloch B. Dopamine receptor gene expression by enkephalin neurons in the rat forebrain. Proc Natl Acad Sci USA 1990;87:230-4.
10. Llorens-Cortes C, Zini S, Gros C, Schwartz JC. Dopaminergic regulation of enkephalin release. J Neurochem 1991;56:1368-75.
11. Schoffelmeer ANM, Hogenboom F, Mulder AH. Inhibition of dopamine-sensitive adenylate cyclase by opioids: possible involvement of physically associated μ- and δ-opioid receptors. Naunyn-Schmiedebergs Arch Pharmacol 1987;335:278-84.
12. Smith JAM, Leslie FM, Broide RS, Loughlin SE. Long-term changes in striatal opioid systems after 6-hydroxydopamine lesion of rat substantia nigra. Neuroscience 1993;55:935-51.
13. Tang F, Costa E, Schwartz JP. Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks. Proc Natl Acad Sci USA 1983;80:3841-4.
14. 5-enkephalin in the human brain. Brain Res 1983;280:379-82.
15. 1A agonists with potential anxiolytic properties. J Pharmacol Exp Ther 1988; 246:745-52.
16. Cesselin F, Bourgoin S, Hamon M, et al. Normal CSF levels of metenkephalin-like material in a case of naloxone reversible congenital insensitivity to pain. Neuropeptides 1984;4:217-25.
17. Cesselin F, Oliveras JL, Bourgoin S, et al. Increased levels of metenkephalin-like material in the CSF of anaesthetized cats after tooth pulp stimulation. Brain Res 1982;237:325-38.
18. Degrell L, Nagy E. Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid. Biol Psychiatry 1990;27:891-6.
19. Furui T, Kageyama N, Haga T, Ichiyama A, Fukushima M. Radioreceptor assay of methionine-enkephalin-like substance in human cerebrospinal fluid. Pain 1980;9:63-72.
20. Toghi H, Abe T, Takahashi S, Takahashi J, Hamato H. Alterations in the concentrations of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neurosci Lett 1993;159: 135-8.
21. Andersen O, Johansson BB, Svennerholm L. Monoamine metabolites in successive samples of spinal fluid. A comparison between healthy volunteers and patients with multiple sclerosis. Ada Neurol Scand 1981;63:247-54.
22. Pezzoli G, Panerai AE, Di Giulio A, Longo A, Passerini D, Carenzi A. Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients. Neurology 1984;34:516-9.
23. Caboche J, Vernier P, Julien JF, Rogard M, Mallet J, Besson MJ. Parallel decrease of glutamic acid decarboxylase and preproenkephalin mRNA in the rat striatum following chronic treatment with a dopaminergic D1 antagonist and D2 agonist. J Neurochem 1991; 56:428-35.
24. Angulo JA. Involvement of dopamine D1 and D2 receptors in the regulation of proenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J Neurochem 1992;58:1104-9.
25. Pollack AE, Woolen GF. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors. Mol Brain Res 1992;12:111-9.
26. Chéramy A, Leviel V, Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature 1981;289:537-42